Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

NCT00721045 is registered in ClinicalTrials.gov with Mesoblast, Ltd. as lead sponsor.

NCT NCT00721045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00721045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
Lead sponsor
Mesoblast, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
July 31, 2013
Enrollment
60 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure